CAS-ViewAlert

View Alert




Originator:		MHRA Drug Alerts
From:		Sandra Bax - Medicines and Healthcare Products Regulatory Agency
Issue date:		12-Mar-2018 10:58:47
This alert has been issued to:
		MHRA (Medicines) Drug Alerts (Various Recipients) NHS Regional Offices NHS Foundation Trusts (England) - Medical Director NHS Trusts (England) - Medical Director Territorial CMOs in Northern Ireland, Scotland & Wales Regional Directors of Public Health
		Clinical Commissioning Groups NHS Foundation Trusts (England) - Chief Executive MHRA (Medicines) Drug Alerts - Non-NHS Recipients Director of Public Health NHS Trusts (England) - Chief Executive
Action category:		Class 3: Action within 5 days
Title:		DRUG ALERT CLASS 3 (ACTION WITHIN 5 DAYS); ASTRAZENECA; LYNPARZA CAPSULE 50MG (OLAPARIB); EU/1/14/959/001
Broadcast content:		AstraZeneca is recalling batch NG327 as the level of olaparib polymorphic form L exceeds the registered specification limit. As a precautionary measure, the other listed batches are also being recalled as they may exceed the limit before the end of their shelf life. Full details of the drug alert are included in the attached PDF file. The AstraZeneca letter to healthcare professionals is also attached for information. Please forward to listed recipients. This information is also published on the MHRA website https://www.gov.uk/drug-device-alerts
Alert reference:		EL(18)A/06
Attachments:		EL (18)A_06.pdf Dear HCP letter.pdf
Cascade to:		#COMMUNITYPHARMACISTS# #DISPENSING GP# #HospitalPharmacy#